Luis Borges, Ph.D.
CSO
LinkedIn profile
Dr. Luis Borges brings over 28 years of scientific and executive leadership across both large and emerging biotechnology companies. A recognized expert in iPSC-derived T and NK cell therapies, he served as Chief Scientific Officer at Century Therapeutics, where he led the preclinical development of multiple iPSC-derived therapies for liquid and solid tumors. Under his leadership, Century’s first product candidate, CNTY-101, advanced into Phase I clinical trials for non-Hodgkin lymphoma and autoimmune diseases.
In addition to Century, Dr. Borges held key leadership roles, including CSO at Metagenomi and Cell Medica, Senior Vice President of Research at Five Prime Therapeutics, and Scientific Director in Amgen’s Hematology and Oncology division. His career is defined by advancing innovative therapies into clinical development and driving scientific and operational excellence.
Dr. Borges earned his Ph.D. in Pathology from the University of Washington School of Medicine.
